Patents by Inventor M. Amin Arnaout
M. Amin Arnaout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110155667Abstract: The invention provides microfluidic devices and methods of using such devices for filtering solutions, such as blood.Type: ApplicationFiled: October 29, 2010Publication date: June 30, 2011Inventors: Joseph L. Charest, Jeffrey T. Borenstein, M. Amin Arnaout
-
Publication number: 20100233135Abstract: The present invention provides compositions and methods featuring ZBP-89 polypeptides or nucleic acid molecules for expanding a hematopoietic stem cell population or for modulating angiogenesis.Type: ApplicationFiled: August 16, 2007Publication date: September 16, 2010Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: M. Amin Arnaout
-
Publication number: 20100136681Abstract: As described in more detail below, the present invention provides cellular compositions for the treatment or prevention of kidney disease. The invention is based, at least in part, on the discovery of a population of cortical peritubular Flk1- and Seal-expressing kidney cells having a high tubulogenic potential.Type: ApplicationFiled: March 18, 2008Publication date: June 3, 2010Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: M. Amin Arnaout
-
Publication number: 20100056503Abstract: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.Type: ApplicationFiled: June 19, 2009Publication date: March 4, 2010Applicant: The General Hospital CorporationInventors: Vineet Gupta, M. Amin Arnaout
-
Publication number: 20090221094Abstract: Methods are disclosed for detecting anthrax protective antigen polypeptides and inhibiting their binding to ?2 integrin ?. A domain polypeptides, for example ?2 integrin receptors. The disclosed methods are useful, for example, in diagnosing the presence of an anthrax toxin in the environment or in a subject and also for reducing anthrax intoxication in a subject. The methods can also be used to identify compounds that inhibit binding of an anthrax toxin to a ?2 integrin.Type: ApplicationFiled: March 30, 2006Publication date: September 3, 2009Inventors: M. Amin Arnaout, Jian-Ping Xiong
-
Publication number: 20090023226Abstract: Polypeptides comprising all or part of a variant integrin ? subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g.Type: ApplicationFiled: January 28, 2008Publication date: January 22, 2009Inventors: M. Amin Arnaout, Rui Li, Jian-Ping Xiong
-
Patent number: 7323552Abstract: Polypeptides comprising all or part of a variant integrin ? subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g.Type: GrantFiled: May 10, 2002Date of Patent: January 29, 2008Assignee: The General Hospital CorporationInventors: M. Amin Arnaout, Rui Li, Jian-Ping Xiong
-
Patent number: 7153944Abstract: Polypeptides comprising all or part of a variant integrin ? subunit A domain or a variant integrin ? subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g.Type: GrantFiled: March 13, 2001Date of Patent: December 26, 2006Assignee: The General Hospital CorporationInventors: M. Amin Arnaout, Rui Li, Jian-Ping Xiong
-
Patent number: 7064180Abstract: Polypeptides comprising all or part of a variant integrin ? subunit A domain or a variant integrin ? subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g.Type: GrantFiled: January 11, 2001Date of Patent: June 20, 2006Assignee: The General Hospital CorporationInventors: M. Amin Arnaout, Rui Li, Jian-Ping Xiong
-
Publication number: 20040086935Abstract: Polypeptides comprising all or part of a variant integrin &agr; subunit A domain or a variant integrin &bgr; subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g.Type: ApplicationFiled: January 11, 2001Publication date: May 6, 2004Inventors: M. Amin Arnaout, Rui Li, Jian-Ping Xiong
-
Publication number: 20030109691Abstract: Polypeptides comprising all or part of a variant integrin &agr; subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g.Type: ApplicationFiled: May 10, 2002Publication date: June 12, 2003Inventors: M. Amin Arnaout, Rui Li, Jian-Ping Xiong
-
Publication number: 20030078375Abstract: Polypeptides comprising all or part of a variant integrin &agr; subunit A domain or a variant integrin &bgr; subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g.Type: ApplicationFiled: March 13, 2001Publication date: April 24, 2003Inventors: M. Amin Arnaout, Rui Li, Jian-Ping Xiong
-
Patent number: 6458588Abstract: Flk-1 positive/Sca-1 negative renal stems cells and uses thereof are described. The cells are useful for the regeneration of damaged kidney tissue, the generation of artificial kidneys and the delivery of transgenes.Type: GrantFiled: April 5, 2001Date of Patent: October 1, 2002Assignee: The General Hospital CorporationInventors: M. Amin Arnaout, Peter G. Linde
-
Publication number: 20020102241Abstract: Flk-1 positive/Sca-1 negative renal stems cells and uses thereof are described. The cells are useful for the regeneration of damaged kidney tissue, the generation of artificial kidneys and the delivery of transgenes.Type: ApplicationFiled: April 5, 2001Publication date: August 1, 2002Inventors: M. Amin Arnaout, Peter G. Linde
-
Patent number: 5877275Abstract: The invention features human CD11 recombinant or synthetic peptide capable of inhibiting a CD11/CD18-mediated immune response, a purified DNA encoding a human CD11b peptide, soluble heterodimeric molecules composed of a CD11 peptide and a CD18 peptide, and a method of controlling any phagocyte-mediated tissue damage such as that associated with reduced perfusion of heart tissue during acute cardiac insufficiency.Type: GrantFiled: June 7, 1995Date of Patent: March 2, 1999Assignee: The General Hospital CorporationInventor: M. Amin Arnaout
-
Patent number: 5424399Abstract: The invention features human CR3.alpha. recombinant or synthetic peptide capable of inhibiting a CR3-mediated immune response, a purified DNA encoding a human CR3.alpha. peptide, and a method of controlling any phagocyte-mediated tissue damage such as that associated with reduced perfusion of heart tissue during acute cardiac insufficiency. As used herein, a human CR3.alpha. recombinant peptide is a chain of amino acids derived from recombinant CR3.alpha.-encoding cDNA, or the corresponding synthetic DNA.Type: GrantFiled: June 16, 1993Date of Patent: June 13, 1995Assignee: The Children's Medical Center CorporationInventor: M. Amin Arnaout
-
Patent number: 5200319Abstract: A purified protein (p29) capable of binding auto-antibodies present in the sera of individuals suffering from Wegener's granulomatosis. The invention also features a monoclonal antibody against the p29 protein and methods of diagnosing Wegener's granulomatosis, pauci-immune necrotizing and/or crescentic glomerulonephritis, and other conditions associated with glomerulonephritis.Type: GrantFiled: October 25, 1990Date of Patent: April 6, 1993Assignee: The General Hospital CorporationInventors: M. Amin Arnaout, Robert T. McCluskey, John L. Niles
-
Patent number: 5091303Abstract: A purified protein (p29) capable of binding autoantibodies present in the sera of individuals suffering from Wegener's granulomatosis. The invention also features a monoclonal antibody against the p29 protein and methods of diagnosing Wegener's granulomatosis.Type: GrantFiled: October 27, 1989Date of Patent: February 25, 1992Assignee: The General Hospital CorporationInventors: M. Amin Arnaout, Robert T. McCluskey, John L. Niles